newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

Aytu enters the over $22 billion United States prescription major depressive disorder market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.EXXUA has